Autologous T cells are genetically engineered to express a chimeric antigen receptor recognizing CD19 and CD20 on B cells; antigen binding activates CAR signaling to expand and activate the T cells, leading to cytokine release and perforin/granzyme-mediated cytotoxic killing of malignant B cells, with on-target depletion of normal B cells.